Bessemer Group Inc. Has $54,000 Stock Holdings in Option Care Health, Inc. (NASDAQ:OPCH)

Bessemer Group Inc. raised its stake in Option Care Health, Inc. (NASDAQ:OPCH) by 62.3% in the 1st quarter, Holdings Channel.com reports. The fund owned 1,560 shares of the company’s stock after buying an additional 599 shares during the quarter. Bessemer Group Inc.’s holdings in Option Care Health were worth $54,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in Option Care Health by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 19,315,421 shares of the company’s stock valued at $448,118,000 after acquiring an additional 75,313 shares in the last quarter. Wellington Management Group LLP raised its holdings in Option Care Health by 84.6% in the 4th quarter. Wellington Management Group LLP now owns 18,325,123 shares of the company’s stock valued at $425,143,000 after acquiring an additional 8,400,208 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Option Care Health by 17.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,988,051 shares of the company’s stock valued at $92,518,000 after acquiring an additional 591,042 shares in the last quarter. Northern Trust Corp raised its holdings in Option Care Health by 11.8% in the 4th quarter. Northern Trust Corp now owns 2,626,478 shares of the company’s stock valued at $60,934,000 after acquiring an additional 278,158 shares in the last quarter. Finally, Norges Bank acquired a new position in Option Care Health in the 4th quarter valued at $60,219,000. 98.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

OPCH has been the subject of several analyst reports. JMP Securities reaffirmed a “market outperform” rating and issued a $36.00 price objective on shares of Option Care Health in a report on Wednesday, June 18th. Barrington Research reissued an “outperform” rating and set a $38.00 price target on shares of Option Care Health in a report on Wednesday, April 30th. UBS Group raised Option Care Health from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $38.00 to $40.00 in a report on Wednesday, April 30th. Finally, JPMorgan Chase & Co. boosted their price target on Option Care Health from $40.00 to $41.00 and gave the stock an “overweight” rating in a report on Thursday, March 6th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $35.50.

Option Care Health Price Performance

Option Care Health stock opened at $30.07 on Friday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.02 and a current ratio of 1.54. Option Care Health, Inc. has a 52 week low of $21.39 and a 52 week high of $35.53. The stock has a market capitalization of $4.92 billion, a P/E ratio of 24.25, a price-to-earnings-growth ratio of 1.87 and a beta of 0.73. The stock has a fifty day moving average of $32.02 and a 200-day moving average of $31.05.

Option Care Health (NASDAQ:OPCH) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.36 by $0.04. The business had revenue of $1.33 billion for the quarter, compared to analyst estimates of $1.26 billion. Option Care Health had a return on equity of 16.90% and a net margin of 4.12%. Option Care Health’s quarterly revenue was up 16.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.26 EPS. On average, sell-side analysts expect that Option Care Health, Inc. will post 1.22 earnings per share for the current fiscal year.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.